Laxmi Organic reported a 33% decline in net profit to ₹79.26 crore for FY26. The company is seeking shareholder approval for minimum remuneration for directors due to inadequate profits, signaling financial strain amid market challenges.
Laxmi Organic Industries Reports Profit Dip, Seeks Remuneration Approval
Laxmi Organic Industries' profit after tax (PAT) fell 33% to ₹79.26 crore in the financial year 2025-26, down from ₹118.02 crore in the prior year. Total revenue also declined to ₹2,823.73 crore from ₹2,969.90 crore.
Reader Takeaway: Profitability challenges persist, but strategic initiatives are underway to drive recovery.
What just happened
Laxmi Organic Industries reported a significant drop in profitability for the financial year ending March 31, 2026. Profit After Tax (PAT) declined by 33% to ₹79.26 crore, compared to ₹118.02 crore in the previous fiscal year. Total revenue also saw a decrease, falling to ₹2,823.73 crore from ₹2,969.90 crore. The operating margin compressed to 4.04% from 6.30%.
Why this matters
The decline in profit and margins indicates significant pressure on the company's earnings. The need to seek shareholder approval for paying minimum remuneration to Executive Directors, due to inadequate profits, highlights financial strain. This could be a concern for investors regarding the company's short-term financial health and profitability outlook.
The backstory
Laxmi Organic Industries, a manufacturer of specialty chemicals, has been navigating a challenging industry environment. Factors such as demand slowdown in key end-user segments, raw material price volatility, global macroeconomic uncertainties, and increased competition have impacted its performance.
What changes now
The company is seeking shareholder approval for a final dividend of ₹0.30 per equity share. Crucially, it requires approval for a special resolution to pay minimum remuneration to its Executive Directors for FY26 and projected shortfalls for FY27 and FY28. This is allowed under Section 197 of the Companies Act, 2013, when profits are insufficient.
Risks to watch
The primary risk highlighted is the continued profitability challenge and margin compression. The company's reliance on seeking special approvals for executive compensation due to inadequate profits signals underlying financial weakness. Intense competition and input cost volatility remain key concerns.
Peer comparison
While specific peer financial data for the same period is not detailed in the filing, the company mentions increased competitive intensity from global suppliers. This suggests a broader industry trend affecting players in the specialty chemicals sector.
Context metrics (time-bound)
- Revenue FY26: ₹2,823.73 crore (down from ₹2,969.90 crore in FY25)
- PAT FY26: ₹79.26 crore (down from ₹118.02 crore in FY25)
- Operating Margin FY26: 4.04% (down from 6.30% in FY25)
- Final Dividend: ₹0.30 per equity share for FY26
What to track next
Investors should closely monitor the company's execution of its strategic initiatives, including capacity expansion, product diversification into higher-margin specialty and fluorine-based intermediates, and cost optimization. The ability to improve EBITDA margins and ROCE as market conditions stabilize will be critical.